Note: Descriptions are shown in the official language in which they were submitted.
CA 02980120 2017-09-18
WO 2016/189132 1 PCT/EP2016/062002
Composition and Method for Disrupting Tissue Material
Description:
Introduction:
The present invention relates to a composition for disrupting tissue samples,
such as in
particular solid tissue, wherein the composition comprises solid disrupting
particles in
combination with at least one enzyme for enzymatic lysis and at least one
chaotropic
agent, for a combined disruption treatment by simultaneous mechanical grinding
or
milling disruption and enzymatic digestion. Further, the invention relates to
a method for
disrupting solid tissue material by simultaneously applying mechanical
grinding or milling
disruption and enzymatic digestion. The invention further relates to a kit and
systems for
carrying out solid tissue disruption in accordance with the present invention.
Background:
The step of disruption of a sample material is one of the first and
fundamental steps in
analytical research, involving separating, isolating, and analyzing the
desired component
(analyte) from an intact sample, in particular in isolation/harvesting and
analysis of
cellular components such as nucleic acids, RNA, DNA, proteins, and other
biochemical
analytes.
In principle, both chemical and mechanical/physical methods are available for
disruption
of biological samples. Chemical methods are usually preferred for many sample
types
such as e.g., E. coli and cultured cells. Mechanical/physical methods, relying
on grinding,
shearing, beating and shocking are generally used for biological samples which
cannot
effectively be disrupted by chemical treatments, such as e.g. many
microorganisms, solid
tissues, solid specimens (e.g. seeds).
Known chemical disruption methods usually make use of so called lysis
solutions or lysis
buffers on the basis of detergents, surfactants, lytic enzymes or chaotropes,
which
disrupt the structure of the biological sample or cells to liberate the
cellular contents or
analytes.
Mechanical or physical disruption methods usually make use of homogenizers,
mortar
and pestles, sonicators, mixer, mills, and vortexers, which mechanically
disrupt the
CA 02980120 2017-09-18
WO 2016/189132 2 PCT/EP2016/062002
structure of the biological sample by grinding, shearing, beating and shocking
forces to
liberate the cellular contents or analytes.
The choice of the disruption and homogenization method strongly depends on the
kind of
biological sample to be treated as well as on the cellular components to be
isolated and
analyzed and the choice of tools, chemistries, and their method of use may
have a
significant impact on the outcome of the analysis.
Solid tissue material is so far usually homogenized or disrupted by applying
several
steps of mechanical disruption techniques as mentioned above or by applying
chemical
(i.e. enzymatic) digestion over an extended period of time (usually over-night
digestion).
However, such methods are time consuming and need special high-performance
mixing
devices to achieve suitable homogenization and sufficient lysis, thereby very
often
deteriorating the isolated sensitive analytes. Grinding with low-power mixer
such as e.g.
a vortexer has been found to be not effective for grinding solid tissue
material.
To use a combination of chemical disruption methods such as e.g. lysis buffers
in
combination with mechanical disruption methods has been mentioned very
generally for
example in D. W. Burden "Guide to the Disruption of Biological Samples ¨ 2012"
(Random Primers, Issue No. 12, pages 1-25, 2012), which provides a broad
overview
over various chemical and mechanical disruption methods for application in the
disruption of various biological samples. The publication leaves open, which
specific
disruption methods out of the various chemical and mechanical methods may be
combined or how (e.g. in subsequent treatment steps or simultaneously) for
which
particular biological sample type. The use of grinding balls with vortexer for
rupturing
tissue is mentioned, but it is pointed out, that vortexer are less suitable
(less effective) for
grinding tissue material due to their poor performance.
In the field of pre-treating biological samples for liberating the desired
analytes, various
homogenization compositions or lysis reagents are known. For example in
WO 2014/096136 A2, EP 2447352 A1, or WO 1999/33559 Al homogenization media
are mentioned, which may comprise a lytic enzyme and mechanical milling
particles. All
of these media are described for being used in the disruption of single cells,
cell cultures,
microorganisms, bacteria, viruses, or spores.
International application WO 2002/00600 Al of the present applicant relates to
a method
for isolating and stabilizing nucleic acids in or from micro-organisms such as
prokaryotes,
CA 02980120 2017-09-18
WO 2016/189132 3 PCT/EP2016/062002
fungi, protozoa or algae. Therein, it is generally mentioned that compact
biological
samples may be homogenized or disrupted by using mechanical, chemical,
physical or
enzymatic methods. In Example 5 cell disruption of a bacteria sample is
described and
therein it is mentioned that the bacterial cell walls are disrupted using
enzymatic lysis
(lysozyme-mediated cell disruption) supported by the use of a bead mill with
glass beads
with a diameter of 150 to 600 pm at a mixing speed of 30 Hz for 5 minutes.
International application WO 2011/144304 Al relates to a lysis buffer and a
method for
the lysis of bodily samples. The lysis buffer as claimed therein comprises
besides at least
one chaotropic agent and at least one reducing agent also at least one
proteolytic
enzyme. The lysis buffer may further comprise bead milling particles and the
method for
processing bodily samples as described therein includes bead-milling of a
mixture
comprising the bodily sample and the lysis buffer with the at least one
proteolytic
enzyme. The application specifically relates to bodily samples that are
relevant for the
diagnosis of respiratory diseases and therein the bodily samples are defined
to comprise
bodily fluids or semi-fluid samples, such as sputum, pus, secretion,
aspirates, lavage,
swab, or non-respiratory samples such as blood, pus, pleural fluid, pleural
punctates,
gastric juice, gastric aspirates, drainages or punctate fluids. The lysis
buffer is mainly
intended for disrupting respiratory samples and mandatorily comprises a
reducing agent
for dissolving mucus constituents in such samples.
EP 2 166 335 Al of the present applicant describes a high-performance bead
milling
device and a method for disrupting solid tissue samples, using such device.
The
Example mentions that the mechanically disrupted tissue sample is subsequently
treated
with proteinase K and RNAse A for further analysis according to a DNeasy
protocol
(available from Qiagen).
WO 2005039722 A2 and the corresponding US 8,020,790 describe disruption of
biological samples by using specific milling particles and a not further
specified lysis
buffer.
Ciccone et al. describe in their scientific publication "A B-cell targeting
virus disrupts
potentially protective genomic methylation patterns in lymphoid tissue by
increasing
global 5-hydroxymethylcytosine levels" (Veterinarys Research 2014, 45, 108)
tissue
disruption for a DNA blot assay using 10 mm glass beads and 10 mM tris, pH
8.0, 100
mM NaCI, 10 mM EDTA, 0.5% SDS. Therein 100 ug proteinase K are added and left
to
stand for protein digestion overnight at 50 C.
CA 02980120 2017-09-18
WO 2016/189132 4 PCT/EP2016/062002
Mann and Babb describe in their scientific publication "Neural steroid hormone
receptor
gene expression in pregnant rats" (Molecular Brain Research 2005, 142, 39-46)
a brain
tissue sample homogenization method using a lysis buffer containing proteinase
K and
two 4 mm grinding beads and carrying out protein digestion at 56 C for 30
minutes,
followed by 30 minutes at -20 C.
As shown above, a specific combination of lytic enzymes and mechanical
disruption
particles for a simultaneous disruption of biological samples has only been
described for
biological sample material, which exhibits a biological structure being
characterized by
comparably small size (microorganisms, cells, viruses etc.) or being
structurally "weak"
(single cells, cell-cultures, bodily fluids). In contrast, solid tissue
material is usually
characterized by a comparably stable cell construct, or fibrous or membranous
structure
and is much more compact as e.g. fluid or semi-fluid samples. Therefore, solid
tissue
material exhibits an enhanced mechanical strength or integrity, a higher
density and is
very often provided or sampled in the form of much larger intact / tightly
connected or
compact sample pieces compared to the smaller and "weaker" sample materials as
described in the prior art above (e.g. cells, cell cultures, microorganisms,
bacteria,
viruses or spores). It is self-evident, that such solid tissue material in
principal needs to
be treated in a totally different way to disrupt and release the desired
analytes. Disrupting
the comparably tight cellular structure affords stronger forces and longer
digestion times
than disrupting a fluid sample or cell culture sample. Applying strong
mechanical or
chemical disruption forces then bears the risk of damaging or deteriorating
the often very
sensitive desired analytes such as e.g. nucleic acids, DNA, RNA and other
cellular
components.
Object of the Invention:
It was an object of the present invention to provide a new and improved method
for
effectively disrupting and homogenizing solid tissue material for isolating
and harvesting
sensitive biochemical analytes, such as e.g. nucleic acids, RNA, DNA and other
cellular
components, which avoids the disadvantages of the prior art methods.
Preferably, the
new and improved method for disrupting solid tissue should be particularly
mild. More
preferably, the new method should provide a mild disruption and homogenization
of solid
tissue samples, improved quality of the isolated analytes, work faster and
simplify the
sample preparation in particular for automated analyses with high throughput.
Even more
preferably, the new and improved method should be carried out by applying mild
mechanical and/or mild chemical impact on the tissue sample, in particular by
applying
CA 02980120 2017-09-18
WO 2016/189132 5 PCT/EP2016/062002
reduced mechanical forces and/or reduced chemical impact. Even more preferred
the
chemical impact of chaotropic agents should be reduced. Further, it is
preferred that the
activity of the lytic enzyme is improved and its inactivation is avoided to
provide its
optimal efficacy in a combined mechanical and chemical (i.e. enzymatic) lysis
treatment
of the tissue sample. It is further preferred to provide a faster method with
shortened
disruption / digestion times.
It was surprisingly found, that with the compositions, kits, systems and the
method
according to the present invention this object has been solved. The
compositions, kits,
systems and the method of the present invention allow effective disruption of
solid tissue
material, even of very tough tissue samples with highly compact or tight
tissue structure
such as e.g. rodent tails (e.g. mouse tails), in a significantly shorter time
period, even
when carried out with usual lab equipment such as low-power vortexer, and
simultaneously achieves higher yields of the desired analytes with better
quality of the
analytes compared to the so far applied homogenization methods for intact
tissue
material.
Surprisingly it turned out, that the present invention in particular improves
the extraction
of DNA out of tissue samples compared to either enzymatic digestion or
mechanical
disruption with bead mills alone. Chemical, i.e. enzymatic digestion alone is
generally
unable to maximize yields extracted out of tissue samples. Mechanical bead
milling
disruption alone usually requires specialized and large equipment (bead mills)
in order to
efficiently homogenize tissue samples for efficient DNA extraction. In the
present
invention it has been shown that the combination of an optimized lysis
chemistry in
combination with an optimized choice of grinding particles allows efficient,
fast, and
complete disruption and homogenization of tissue samples, even on common
desktop
vortexers, thereby massively improving the yield compared to using chemical,
i.e.
enzymatic digestion alone, and in addition, surprisingly the quality
(especially the size) of
the extracted nucleic acid was not deteriorated by the milling procedure and
turned out to
be superior to that as achieved by usual bead milling treatments.
It has in particular surprisingly been found that with the specific
combination of the
mechanical milling conditions and the specific chemical lysis conditions of
the present
invention a more than additive effect in the sense of a kind of synergistic
effect can be
achieved, compared to applying either the mechanical milling conditions or the
specific
chemical lysis conditions alone.
CA 02980120 2017-09-18
WO 2016/189132 6
PCT/EP2016/062002
Description of the Invention:
The subject matter of the present invention are new compositions and methods
for the
disruption and homogenization of tissue material.
In the context of the present invention the term "tissue material" or "tissue"
relates in
particular to human and animal derived solid tissue samples, such as in
particular whole
or intact tissue samples. The term "tissue material" or "tissue" includes
cellular
organizational level intermediates between cells and a complete organ as well
as
samples of human or animal bodies comprising such cellular organizational
level
intermediates. The solid tissue material in the sense of the present invention
is usually
characterized by a comparably stable cell construct or cell organization, or a
fibrous or
membranous structure. Usually such tissue material is tougher and much more
compact
or tightly connected as e.g. simple cell cultures or fluid or semi-fluid
samples.
Accordingly, solid tissue material in the sense of the present invention
exhibits an
enhanced mechanical strength or integrity, a higher density and is very often
sampled in
the form of much larger intact / tightly connected or compact sample pieces
compared to
small and "weak" sample materials as described in the prior art above (e.g.
single cells,
cell cultures, microorganisms, bacteria, viruses or spores). In particular
tissue material
according to the present invention comprises, without being limited,
connective tissue,
muscle tissue, nervous tissue, epithelial tissue and mineralized tissue.
Accordingly,
tissue in the sense of the present invention includes ¨ without being limited
¨ organized
(connected) cell constructs, fibrous and/or membranous tissue, comprising for
example
skin, muscle, tendons, filaments, nerves, cartilage, bone, organs, such as for
example
intestine, gastric, liver, spleen, brain, lymph, bone marrow, kidney, heart,
as well as tail
(such as rodent tail, e.g. mouse tail) etc. Preferably, the tissue material as
used in the
present invention is the result of a biopsy. More preferably, the tissue
material as used in
the present invention is solid tissue compared to fluid or semi-fluid samples
such as e.g.
blood, mucous membrane. Further, it is preferred that the tissue material as
used in the
present invention is tough solid tissue compared to weak single cells or cell
cultures.
In the context of the present invention the term "disruption" or "disrupting"
comprises all
levels of disruption of the sampled and treated tissue material, which allows
liberation or
release of cellular components or the desired analytes from the tissue sample
in an
amount above the individual detection limit of the respective analyte or in an
amount
which allows isolation, harvesting and detection with suitable analysis
techniques.
Therein, a high degree of disruption includes complete or at least partial
homogenization
CA 02980120 2017-09-18
WO 2016/189132 7 PCT/EP2016/062002
of the tissue sample. Homogenization means that the tissue sample is brought
to a state
such that all (or at least the homogenized parts) of the fractions of the
sample are
essentially equal in composition. This means that a homogenized sample is
disintegrated, milled or minced and then mixed so well that removing some of
the sample
does not alter the overall molecular make-up of the remaining sample, and is
identical to
the removed fraction. Preferably the composition, kit and systems as well as
the method
of the present invention relates to disruption and/or homogenization of tissue
material.
The composition for the disruption of tissue material according to the present
invention
comprises
- one or more solid disrupting particles; and
- at least one enzyme for enzymatic lysis.
Preferably the composition for the disruption of tissue material according to
the present
invention comprises
- one or more solid disrupting particles;
- at least one enzyme for enzymatic lysis; and
- at least one buffer.
More preferably the composition for the disruption of tissue material
according to the
present invention comprises
- one or more solid disrupting particles;
- at least one enzyme for enzymatic lysis;
- at least one buffer; and
- at least one chaotropic agent, preferably in a total concentration of
chaotropic agent
below or equal to 1 M.
More preferably the composition for the disruption of tissue material
according to the
present invention comprises
- one or more solid disrupting particles;
- at least one enzyme for enzymatic lysis;
- at least one buffer; and
- at least one anti-foaming agent.
More preferably the composition for the disruption of tissue material
according to the
present invention comprises
- one or more solid disrupting particles;
CA 02980120 2017-09-18
WO 2016/189132 8 PCT/EP2016/062002
- at least one enzyme for enzymatic lysis;
- at least one buffer;
- at least one chaotropic agent, preferably in a total concentration of
chaotropic agent
below or equal to 1 M; and
- at least one anti-foaming agent.
In a further preferred embodiment, the composition for the disruption of
tissue material
according to the present invention further comprises one or more agents
selected from
- at least one chaotropic agent;
- at least one detergent;
- at least one nuclease inhibitor;
- at least one anti-foaming agent;
- at least one osmotic stabilizer;
- at least one reducing agent,
and any mixture thereof.
Further preferred embodiments relate to the compositions for the disruption of
tissue
material as defined above, comprising one or more solid disrupting particles,
at least one
enzyme for enzymatic lysis, at least one buffer, at least one chaotropic
agent, preferably
in a total concentration of chaotropic agent below or equal to 1 M, and/or at
least one
anti-foaming agent and one or more agents selected from
- at least one detergent;
- at least one nuclease inhibitor;
- at least one reducing agent;
and any mixture thereof.
It is particularly preferred that the compositions for the disruption of
tissue material as
defined above do not comprise an organic solvent, such as in particular
alcohols, in
concentrations which effect denaturation and thus inactivation of the at least
one lytic
enzyme. For example ethanol, propanol and/or iso-propanol should not be
present in the
composition of the present invention in an amount which denatures or
inactivates the
enzymes (such as in particular the lytic enzymes as defined below,
specifically proteases
such as particularly proteinase K). Most preferably, the compositions of the
present
invention do not comprise organic solvents, in particular no alcohols, very
particularly no
methanol, ethanol, propanol and/or iso-propanol.
CA 02980120 2017-09-18
WO 2016/189132 9 PCT/EP2016/062002
Solid disrupting particles in the context of the present invention comprise
solid particles,
preferably in the form of solid beads, spheres, balls, cones, cylinders,
cubes, triangles,
rectangles and similar suitable geometric forms as well as irregular shapes,
for example
so-called ballcones and satellites (shaped like Saturnõ planet or UFO), for
effecting a
disruption of the tissue material when mixing or milling forces are applied to
the tissue
sample in the composition of the present invention. However, the solid
disrupting
particles should be selected in view of not deteriorating or disrupting the
released cellular
components or analytes.
To achieve sufficient disruption and homogenization of the tissue material and
undamaged liberation of the desired analytes for further isolation, harvesting
and
analysis it is preferred that the solid disrupting particles of the present
invention are solid
inert particles, i.e. particles made of a material, which does not react with
the tissue
material, with any of the reagents of the composition and in any case not with
the desired
analytes to be liberated upon disruption. It is particularly preferred that
the isolated
analytes are not adsorbed by or do not adhere to the inert solid disrupting
particles.
Suitable inert materials comprise for example inert metals, steel, stainless
steel, metal
oxides, glass (silica), plastic, and ceramic. Examples of inert materials
comprise Zr02,
5i02, A1203, Fe203, Ti02, zirconium silicate, metals and alloys from tantalum,
platinum,
etc.. Further suitable inert disrupting materials are known from commercially
available
inert disrupting particles. It is also possible to use mixtures of one or more
kind of
disrupting particles, i.e. use disrupting particles of different forms and/or
made of different
inert materials.
It is further preferred that the disrupting particles exhibit a sufficient
hardness so that no
abrasion occurs during the milling or grinding process.
Preferred are beads, spheres or balls (so called milling beads), preferably
stainless steel
beads, ceramic beads, such as in particular zirconium beads. More preferred
are
irregularly shaped irregularly shaped milling particles such as ballcones or
satellites, in
particular made of steel or stainless steel.
To achieve sufficient disruption forces to effectively disrupt and in
particular homogenize
the treated tissue sample the disrupting particles should preferably exhibit a
comparably
large size - compared to the beads as used in the prior art for disrupting
microorganisms
or cell cultures, which have a size of 100 pm to approximately 600 pm.
Increasing the
amount of small sized beads (100 pm to about 600 or 800 pm beads) for
increasing the
CA 02980120 2017-09-18
WO 2016/189132 10 PCT/EP2016/062002
disruption forces is not a suitable approach, as the high amount of such small
particles
damages or even destroys the sensitive analytes such as in particular DNA.
It is therefore preferred that the disrupting particles according to the
present invention
exhibit a size of at least 1 mm, preferably more than 1 mm. More preferably
the particles
exhibit a size of at least 1.5 mm, more preferably of more than 2 mm (>2 mm),
preferably more than 2.5 mm. Further, the disrupting particles may preferably
exhibit a
size of at least 3 mm 3 mm), more preferably of at least 4 mm, more preferred
of at
least 5 mm.
It is further preferred that the disrupting particles according to the present
invention
exhibit a size of up to 15 mm, preferably up to 12 mm, more preferably up to
11.5 mm.
The disrupting particles according to the present invention may exhibit a size
of 1 mm or
more than 1 mm to 15 mm, 1.5 mm to 15 mm, more than 2 mm to 15 mm, 2.5 mm to
15
mm, 3 mm or more than 3 mm to 15 mm, 4 mm to 15 mm. The particles may further
exhibit a size of 1 mm or more than 1 mm to 12 mm, 1.5 mm to 12 mm, more than
2 mm
to 12 mm, 2.5 mm to 12 mm, 3 mm or more than 3 mm to 12 mm, 4 mm to 12 mm.
Further, the disrupting particles may exhibit a size of 1 mm or more than 1 mm
to 11.5
mm, 1.5 mm to 11.5 mm, more than 2 mm to 11.5 mm, 2.5 mm to 11.5 mm, 3 mm or
more than 3 mm to 11.5 mm, 4 mm to 11.5 mm. The particles may further exhibit
a size
of 1 mm or more than 1 mm to 7 mm, 1.5 mm to 7 mm, more than 2 mm to 7 mm, 2.5
mm to 7 mm, 3 mm or more than 3 mm to 7 mm, 4 mm to 7 mm. Most preferred is a
size
of 3 mm or more than 3 mm to 7 mm or of 4 mm to 7 mm.
The defined sizes of the disrupting particles indicate the longest distance
between two
opposite points of the respective particle. Accordingly, in the case of round
or essentially
round particles (beads, balls, spheres), the defined size relates to the
diameter. In the
case of irregularly shaped particles such as satellites or ballcones the
longest distance
between two opposite points is usually the diameter of the "saturn-like ring"
surrounding
the ball or ballcone part of such particles.
Depending on the size of the disrupting particles, one or more disrupting
particles can be
used. In the case of very large particles, the desired results of disruption
and
preservation of the analytes may be achieved with only one particle (in
particular one ball
or ballcone). It is preferred to use one disrupting particle.
CA 02980120 2017-09-18
WO 2016/189132 11 PCT/EP2016/062002
Suitable disrupting particles comprise 1.0 to 1.7 mm beads, 2.8 to 3.0 mm
beads, 7/64"
grinding balls (approximately 2.8 mm) (in particular stainless steel grinding
balls), 5/32"
grinding balls (approximately 6.0-7.0 mm), 6 mm particles (in particular
zirconium
satellites), 3/8" grinding balls (approximately 9.5 mm) and 7/16" grinding
balls
(approximately 11.1 mm). Preferred are 5/32" beads, and essentially round 5 mm
particles (e.g. beads, balls, spheres). Further examples of commercially
available
particles of irregular shape, ballcones or satellite-shaped particles, which
are also
preferred, exhibit the following sizes:
Sizes [mm]
ball diameter x ball diameter ring diameter height
ring diameter l (A) (B) (top of the cone to the opposite
located side of the ball
(C)
3 x 5 mm 3 mm 5 mm 3.6 mm
4 x 6 mm 4 mm 6 mm 4.7 mm
5 x 7 mm 5 mm 7 mm 5.7 mm
6.5 x 8.5 mm 6.5 mm 8.5 mm 8 mm
Therein, one half of the steel ball-cone is a semi-sphere (ball (A)), the
other half is a cone
and both are separated by a sloping central flange (ring (B)).
It is also possible to use mixtures of disrupting particles of different
sizes. Further it is
possible to mix disrupting particles of any form, material and size, as
defined herein.
The enzyme for enzymatic lysis according to the present invention is selected
from the
group of hydrolases (according to the group EC3 in the EC number
classification of
enzymes). In particular, the at least one enzyme for enzymatic lysis is
selected from the
group of proteases (EC 3.4), which are often also designated as peptidases,
proteinases,
or proteolytic enzymes. Preferably, the at least one enzyme for enzymatic
lysis is
selected from the group of proteinaseK, collagenase, dispase, trypsin, pepsin,
most
preferred is proteinaseK.
Besides the at least one enzyme for enzymatic lysis (proteolytic enzyme) at
least one
additional enzyme, other than the enzyme for enzymatic lysis, may be added.
Preferably,
such additional enzyme is selected from the group of hydrolases acting on
ester bonds
according to enzyme class EC 3.1. Preferably as such an additional enzyme an
RNase
may be added, preferably RNase A is added.
CA 02980120 2017-09-18
WO 2016/189132 12 PCT/EP2016/062002
The at least one buffer according to the present invention may be any buffer,
which is
suitable for receiving the tissue sample, the at least one enzyme for
enzymatic lysis (the
proteolytic enzyme(s)) and the one or more optional additional agents in the
composition
of the present invention. In particular, the buffer must be compatible with
the enzyme for
enzymatic lysis and must not completely inhibit the activity of the
proteolytic enzyme or of
any additional agent of the composition. Preferably, a buffer may be chosen,
which
stabilizes the isolated analytes such as e.g. isolated nucleic acids, DNA, RNA
or other
cellular components. Suitable buffers comprise TRIS buffer, PBS buffer, Good's
buffers,
SSC, sodium citrate, sodium acetate, phosphate buffers, and biological
buffers, selected
from the list comprising for example MES, Bis-Tris, ADA, ACES, PIPES, MOPSO,
Bis-
Tris Propane, BES, MOPS, TES, HEPES, DIPSO, MOBS, TAPSO, Trizma,
HEPPSOPOPSO, TEA, EPPS, Tricine, Gly-Gly, Bicine, HEPBS, TAPS, AMPD, TABS,
AMPSO, CHES, CAPSO, AMP, CAPS, CABS. Preferred are buffers having a pH 6
(equal to or above 6). If the desired analyte to be liberated from the tissue
material is
DNA, then a buffer having a pH 7 (equal to or above 7) is preferred. If the
desired
analyte to be liberated from the tissue material is RNA, then a buffer having
a pH 6
(equal to or above 6) is preferred. Particularly preferred are the buffers
from the list of
biological buffers above. More preferably the at least one buffer is selected
from TRIS
buffer, PBS buffer.
Chaotropic agents (or chaotropes) are effective to support or increase
chemical
digestion, may help to reduce nuclease activity and help to denature proteins,
which can
cause havoc on freshly homogenized samples. According to the present
invention, in
principle all common chaotropes may be used, such as for example sodium
iodide,
guanidine hydrochloride (guanidine HCI, GuHCI), guanidinium thiocyanate (GTC),
guanidine isothiocyanate, and urea. Guanidinium hydrochloride is preferred in
the
present invention. The addition of a chaotrope is particularly suitable, when
the disrupted
tissue material is intended for subsequent nucleic acid isolation procedures,
in particular
procedures which use silica based resins/gels for purification of the isolated
nucleic acid
analytes. Further, chaotropes are particularly preferred, when the desired
released
analyte is RNA.
Generally, chaotropes are used at comparably high molarities. For example
guanidine
salts are usually used at 6 M concentrations, in particular for RNA isolation.
Sodium
iodide is also generally used at 6 M. Urea is often used at 9.5 M. The
inventors of the
present invention surprisingly found that the new compositions, kits and
systems and the
CA 02980120 2017-09-18
WO 2016/189132 1 3 PCT/EP2016/062002
method of the present invention allows a significantly reduced concentration
of
chaotropic agents and it is thus preferred that the concentration of the at
least one
chaotropic agent (total concentration of chaotropic agents) is about up to 1
M, preferably
equal to or less than 1 M (1 M). In particular it is preferred to use
chaotropes in a (total)
concentration of from 0.5 M to 1 M. The use of the reduced concentrations of
chaotropic
agent of not more than 1 M is advantageous as chaotropes such as GuHCI and GTC
are
toxic and a reduction thereof is thus desired for safety reasons and to
protect the users
of such compositions. Further, high concentrations of chaotropes will decrease
the
effectiveness of proteinaseK, due to their protein denaturing effects.
Accordingly,
reducing the concentration of chaotropes, in particular to not more than 1M,
effects a
reduced chemical impact on the tissue sample and allows to provide a more
gentle or
mild lysis composition.
Surfactants (often also designated as detergents) may support the lysis of the
tissue
sample and support solubilization of the homogenate. The addition of at least
one
surfactant is particularly preferred for disruption of fatty tissue such as
liver or brain.
Surfactants comprise ionic surfactants such as anionic and cationic
surfactants,
zwitterionic surfactants and non-ionic surfactants.
The group of anionic surfactants comprises for example sodium dodecyl sulfate
(SDS),
sodium deoxycholate, sodium lauryl ether sulfate (SLES, sodium laureth
sulfate), and
sodium myreth sulfate, with SDS being preferred.
The group of cationic surfactants comprises for example cetyltrimethylammonium
bromide (CTAB), cetyl trimethylammonium chloride (CTAC), cetylpyridinium
chloride
(CPC), benzalkonium chloride (BAC), benzethonium chloride (BZT), 5-bromo-5-
nitro-1,3-
dioxane, dimethyldioctadecylammonium chloride, cetrimonium bromide,
dioctadecyldimethylammonium bromide (DODAB).
The group of non-ionic surfactants comprises for example Triton X-100, Tween
20
(polysorbate 20, polyoxyethylene (20) sorbitan monolaurate), Brij-35
(polyalkylenglycolether), NP-40 (nonyl phenoxypolyethoxyl ethanol), Nonidet P-
40
(octylphenoxypolyethoxyethanol), with Triton X-100 and Tween 20 being
preferred.
The group of zwitterionic surfactants comprises for example phospholipids
phosphatidylserine, phosphatidylethanolamine, phosphatidylcholine, and
sphingomyelins.
CA 02980120 2017-09-18
WO 2016/189132 14 PCT/EP2016/062002
Preferably the at least one surfactant is selected from the group of non-ionic
surfactants
as defined above. More preferably, the at least one surfactant is selected
from the group
consisting of SDS, Tween20 and Triton X-100. Even more preferred the at least
one
surfactant is selected from Tween20 and Triton X-100, and it is very
particularly preferred
to use a combination of both, Tween20 and Triton X-100.
Nuclease inhibitors according to the present invention comprise for example
EDTA,
PMSF, pepstatin A, leupeptin, aprotinin. Preferably the at least one nuclease
inhibitor is
EDTA.
Further, it is possible to add at least one anti-foaming agent (or defoamer),
which may
reduce and prevent the formation of foam in the reaction mixture and thus
improve the
further processability. Anti-foaming agents may be used to prevent formation
of foam or
may be added to break an already formed foam. In principle, all commonly used
anti-
foaming agents can be used, such as for example insoluble oils,
polydimethylsiloxanes
and other silicones, certain alcohols, stearates and glycols ¨ provided that
they do not
negatively affect any of the reaction agents, the tissue sample, the isolated
analytes or
disturb any subsequent isolation, harvesting and analysis methods. A preferred
anti-
foaming agent is polydimethylsiloxane.
Osmotic stabilizers may be added to help bind up water and prevent
dissociation of
related solutes. Osmotic stabilizers comprise for example sucrose or sorbitol.
As osmotic stabilizers may interfere with the cell lysis, the presence of an
osmotic
stabilizer is less preferred, and it is even more preferred not to add osmotic
stabilizers
and thus further improve tissue disruption and homogenization with the
compositions of
the present invention.
According to the present invention it is also possible to add at least one
reducing agent.
Reducing agents may particularly be added, when the desired analyte to be
isolated from
the disrupted tissue is RNA, as the reducing agent reduces RNase. Reducing
agents
comprise for example glutathione, dithiothreitol, and P-mercaptoethanol
Very particularly it is preferred that the compositions of the present
invention comprise a
reducing agent if the desired analyte is RNA and that in such case the
composition does
not comprise a RNase.
CA 02980120 2017-09-18
WO 2016/189132 15
PCT/EP2016/062002
However, as reducing agents may cause undesired side-reactions and are
uncomfortable in the working process (e.g. due to off odors) it is preferred
not to add
reducing agents to the compositions, kits and systems or in the method of the
present
invention. In particular when the desired analyte to be isolated from the
disrupted tissue
is DNA the addition of a reducing agent is avoided or preferably even
excluded.
Therefore, a preferred embodiment of the present invention relates to a
composition
according to the present invention, which consists of
- one or more solid disrupting particles;
- at least one enzyme for enzymatic lysis;
- at least one buffer, preferably selected from TRIS and PBS buffer;
- at least one chaotropic agent, preferably guanidinium hydrochloride;
and optionally one or more agents selected from
- at least one surfactant, preferably selected from the group of non-ionic
surfactants,
preferably selected from Tween20 and Triton X-100;
- at least one nuclease inhibitor, preferably EDTA;
- at least one anti-foaming agent, preferably polydimethylsiloxane;
- at least one osmotic stabilizer, preferably selected from sucrose and
sorbitol; and
- at least one further enzyme selected from the group of RNases, preferably
RNase.
A further preferred embodiment of the present invention relates to a
composition
according to the present invention, which consists of
- one or more solid disrupting particles;
- at least one enzyme for enzymatic lysis;
- at least one buffer, preferably selected from TRIS and PBS buffer;
- at least one chaotropic agent, preferably guanidinium hydrochloride;
- at least one surfactant, preferably selected from the group of non-ionic
surfactants,
preferably selected from Tween20 and Triton X-100;
- at least one nuclease inhibitor, preferably EDTA; and
- at least one further enzyme selected from the group of RNases, preferably
RNase.
A further preferred embodiment of the present invention relates to a
composition
according to the present invention, which consists of
- one or more solid disrupting particles;
- at least one enzyme for enzymatic lysis;
- at least one buffer, preferably selected from TRIS and PBS buffer;
CA 02980120 2017-09-18
WO 2016/189132 16
PCT/EP2016/062002
- at least one chaotropic agent, preferably guanidinium hydrochloride;
- at least one surfactant, preferably selected from the group of non-ionic
surfactants,
preferably selected from Tween20 and Triton X-100; and
- at least one nuclease inhibitor, preferably EDTA.
A further preferred embodiment of the present invention relates to a
composition
according to the present invention, which consists of
- one or more solid disrupting particles;
- at least one enzyme for enzymatic lysis;
- at least one buffer, preferably selected from TRIS and PBS buffer;
- at least one chaotropic agent, preferably guanidinium hydrochloride;
- at least one surfactant, preferably selected from the group of non-ionic
surfactants,
preferably selected from Tween20 and Triton X-100; and
- at least one further enzyme selected from the group of RNases, preferably
RNase.
A further preferred embodiment of the present invention relates to a
composition
according to the present invention, which consists of
- one or more solid disrupting particles;
- at least one enzyme for enzymatic lysis;
- at least one buffer, preferably selected from TRIS and PBS buffer;
- at least one chaotropic agent, preferably guanidinium hydrochloride; and
- at least one surfactant, preferably selected from the group of non-ionic
surfactants,
preferably selected from Tween20 and Triton X-100.
The present invention further relates to a kit for disrupting tissue material,
the kit
comprising
- one or more solid disrupting particles;
- at least one enzyme for enzymatic lysis;
- at least one buffer, preferably selected from TRIS and PBS buffer;
- at least one chaotropic agent, preferably guanidinium hydrochloride;
and optionally one or more agents selected from
- at least one surfactant, preferably selected from the group of non-ionic
surfactants,
preferably selected from Tween20 and Triton X-100;
- at least one nuclease inhibitor, preferably EDTA;
- at least one anti-foaming agent, preferably polydimethylsiloxane;
- at least one osmotic stabilizer, preferably selected from sucrose and
sorbitol;
CA 02980120 2017-09-18
WO 2016/189132 17 PCT/EP2016/062002
- at least one reducing agent, preferably selected from glutathione,
dithiothreitol and
beta-mercaptoethanol;
- at least one further enzyme selected from the group of RNases, preferably
RNase;
and
- optionally a container for receiving the tissue material; and further
- at least one organic solvent, preferably selected from alcohols,
preferably ethanol
and/or isopropanol;
- and a leaflet with instructions for processing the tissue material.
It is particularly preferred that the kit comprises a reducing agent if the
desired analyte is
RNA and in such case it is further preferred that the kit does not comprise a
RNase.
The container for receiving the tissue material may be any suitable container
or reaction
vessel, which is inert with respect to the agents used in the disruption
treatment, which
exhibits enough mechanical stability to withstand the milling or grinding
forces of the
disrupting particles without being destroyed or abraded, which exhibits a
suitable size for
receiving the sample material, the lysis solution and the one or more selected
disrupting
particle and still provides suitable space to allow agitation and movement of
the inserted
components to effect tissue disruption, and which can suitably be used with
the device
which is used for effecting the milling or grinding of the tissue material by
the disrupting
particles. Suitable container or reaction vessels (tubes) are known and
commonly
available.
The addition of an organic solvent such as in particular of at least one
alcohol to the
readily disrupted and/or homogenized tissue sample is advantageous for
providing
excellent binding conditions of the liberated analytes onto silica surfaces in
subsequent
purification, isolation and harvesting steps, as described below in more
detail. Suitable
alcohols to be included in a kit comprise ¨ without being limited ¨ methanol,
ethanol,
propanol, iso-propanol, etc. Preferably ethanol and/or iso-propanol is added.
As
explained above, organic solvents effect denaturation and thus potentially
inhibit the at
least one lytic enzyme of the composition for disrupting the tissue sample.
Accordingly,
the organic solvents in such kits are separated from the compounds for the
tissue
disruption and are added after the tissue disruption has been carried out.
Further embodiments of a kit according to the present invention comprise a
combination
of components (reagents) corresponding to any of the compositions as defined
above for
the tissue disruption and optionally a container for receiving the tissue
material and at
CA 02980120 2017-09-18
WO 2016/189132 1 8 PCT/EP2016/062002
least one organic solvent, preferably selected from alcohols, preferably
ethanol and/or
isopropanol and a leaflet with instructions for processing the tissue
material.
The kit according to the present invention may further comprise suitable
components for
carrying out the above mentioned subsequent binding, purification, isolation
and
harvesting steps. It is particularly preferred to provide a combination of the
above
mentioned kit for effecting tissue disruption according to the invention in
combination with
a binding buffer comprising a chaotropic agent and iso-propanol. However, it
is also
possible to use and provide the above mentioned kit for effecting tissue
disruption
according to the invention in combination with known and commercially
available test kits
for carrying out DNA or RNA binding, as well as with commercially available
test kits for
carrying out DNA or RNA purification and analysis. Accordingly, the above
mentioned
kits may further comprise compounds corresponding to available test kits such
as for
example DNeasy or RNeasy kits (available from Qiagen) or the respective test
kits
themselves and/or materials for absorption and purification such as suitable
silica based
membranes, columns (for example QIAamp columns available from Qiagen) or
silica
magnetic beads.
The present invention further relates to a system (a combination, kit-of-
parts) comprising
a composition or a kit as defined above and a device for effecting the
mechanical milling
or grinding of the tissue material by the disrupting particles.
Such device for effecting the mechanical milling or grinding may be any common
device
used in grinding or bead milling techniques, comprising for example high-power
mixing
mills, high-performance mixer or mills, high-speed mixer, common bead mills as
well as
low-power mixers, such as common laboratory vortexer, bench-top vortexer, or
common
lab shaker (e.g. horizontal shaker).
As mentioned above, from the prior art it was already known to use milling
beads and
bead mills for disrupting intact tissue material. However, for achieving
efficient
homogenization of the tissue material generally specialized and large milling
equipment
such as bead mills or high-power / high-performance mixer had to be used. The
present
invention now surprisingly provided a possibility for disrupting or
homogenizing tissue
material efficiently, fast and completely, even with low-power mixers such as
common
desktop vortexers, which belong to the standard equipment of nearly every
laboratory.
Accordingly, as a device for effecting the milling or grinding of the tissue
low-power
CA 02980120 2017-09-18
WO 2016/189132 19
PCT/EP2016/062002
mixer, including in particular vortexer or horizontal shaker, are preferred.
Particularly
preferred are vortexer.
High-power or high-performance mixer or mills usually work with a frequency of
15 to 60
Hz.
Low-power mixer such as in particular common vortexer usually work with a
force of 150
up to 3200 rpm.
Applying a reduced mechanical power, e.g. from a low-power mixer or vortexer
is
advantageous for preserving the quality of the released analytes and avoid
damages or
deterioration of the analytes due to massive mechanical impact.
A further object of the present invention relates to a system (a combination,
kit-of-parts)
comprising a composition, a kit or the system as defined above, and further
comprising a
tissue material, which is intended for disruption by the composition, kit or
system of the
present invention. Regarding the tissue material of such system, reference is
made to
the above definition of "tissue material".
The present invention further relates to a new method for disrupting or
homogenizing
tissue material, wherein the tissue material is subjected to a simultaneous
treatment of
- mechanical disruption by grinding, milling or beating and
- chemical disruption by enzymatic lysis,
by grinding, milling or beating the tissue material in a lysis solution which
comprises at
least one enzyme for enzymatic lysis.
The method according to the present invention is characterized in that the
grinding,
milling or beating of the tissue material is effected by one or more solid
disrupting
particles as defined above. With respect to preferred embodiments and
selections,
reference is made to the embodiments and selections as defined above.
The method according to the present invention is preferably characterized in
that the
disruption of the tissue material is carried out or effected by using a device
for effecting
the milling or grinding of the tissue as defined above, such as preferably
high-power
mixing mills, high-speed mixers, or low-power mixers including vortexers, in
particular by
using low-power mixers or vortexers as defined above.
CA 02980120 2017-09-18
WO 2016/189132 20
PCT/EP2016/062002
The method according to the present invention is preferably carried out by
using any of
the compositions, kits or systems (combinations, kit-of-parts) as defined
above.
It is particularly preferred, that when carrying out the method of the present
invention
organic solvents, such as in particular alcohols are not present in the
compositions for
the disruption of tissue material in concentrations which effect denaturation
and thus
inactivation of the at least one lytic enzyme. As defined above, for example
ethanol,
propanol and/or iso-propanol should not be present in an amount which
denatures or
inactivates the enzymes. Most preferably, no organic solvents, in particular
no alcohols,
very particularly no ethanol, propanol and/or iso-propanol are present when
carrying out
the method of disrupting the tissue material.
The method according to the present invention is in particular characterized
by
comprising the steps:
(i) adding to a tissue material in a suitable container (e.g. as defined above
in context
with the kit)
a) one or more solid disrupting particles, the at least one buffer, the at
least one
enzyme for enzymatic lysis, the at least one chaotropic agent, optionally an
RNase, and optionally one or more agents selected from, surfactants, reducing
agents, nuclease inhibitors, anti-foaming agents or mixtures thereof, or
b) any of the composition as defined above;
(ii) optionally closing the container;
(iii) disrupting the tissue material in the container using a high-power
mixing mill, a high-
speed mixer, or a low-power mixer, including a vortexer, preferably by using a
vortexer;
(iv) incubating the mixture of step (iv) at elevated temperature, preferably
above 24 C,
more preferably between 25 and 70 C;
(v) optionally repeating step (iii) and (iv);
(vi) optionally providing the resulting mixture for subsequent purification,
separation,
extraction and/or analytic process steps; or alternatively storing the
resulting mixture,
preferably after deactivation of the lytic reagents, in particular the lytic
enzymes, e.g. by
addition of a suitable reagent for deactivation and/or by cooling or freezing
of the
resulting mixture.
The preferred milling time according to step (iii) is about 1 minute,
preferably about 30
seconds to about 15 minutes, preferably about 30 seconds to about 5 minutes.
When a
high-power or high-performance mixer or mill is used, the milling time is
preferably about
CA 02980120 2017-09-18
WO 2016/189132 21 PCT/EP2016/062002
30 seconds. When a low-power mixer such as in particular a vortexer is used,
the milling
time is preferably about 5 minutes.
The lysis time according to step (iv) does preferably not exceed 4 hours, more
preferably
3 hours, even more preferably 2 hours, much more preferably 1 hour and even
more
preferred less than 1 hour such as particularly less than 30 minutes. If step
(iv) is
repeated (step (v)), then the total lysis time should not exceed 4 hours,
preferably 3
hours, more preferably 2 hours, much more preferably 1 hour and even more
preferred
less than 1 hour such as particularly less than 30 minutes. Preferably, the
lysis time
according to step (iv) (or the total lysis time respectively) is at least 5
minutes, more
preferably at least 10 minutes. Preferably with the method of the present
invention a
sufficient tissue disruption can be achieved to be completed in 15 minutes.
In particular, when the method is used for DNA extraction, the defined lysis
times are
preferred.
It is in particular preferred that the tissue material is not in contact with
the lysis solution
of the present invention for more than 4, preferably 3, more preferably 2
hours, much
more preferably more than 1 hour and even more preferred more than 30 minutes.
Very
particularly an over-night digestion (at least 8 hours digestion) shall be
avoided. In
particular, when the method is used for DNA extraction.
With the compositions, kits, systems (combinations, kit-of-parts) and method
of the
present invention the disruption and homogenization time can be significantly
reduced
down to 1 or 2 hours and even more to 30 minutes or even less, such as
particularly to
not more than about 15 minutes. In contrast, common techniques need a minimum
average digestion time of at least 150 minutes (2.5 hours), while over-night
digestion (at
least 8 hours digestion) is usual.
The present invention is particularly suitable for extracting nucleic acids,
DNA, RNA,
miRNA (microRNA), mRNA, tRNA, rRNA, etc. from tissue material as defined
above.
It is particularly preferred to use the present invention for extracting DNA,
RNA and
miRNA out of tissue samples, extraction of DNA is very particularly preferred.
Thus, the method of the present invention may comprise one or more additional
steps,
subsequent to step (vi) above, comprising
CA 02980120 2017-09-18
WO 2016/189132 22 PCT/EP2016/062002
- collection of the processed material;
- stabilization of the processed material; e.g. by inactivating the lytic
agents, in
particular the lytic enzymes, e.g. by freezing the mixture;
- storing the processed (and stabilized) material;
- binding of the analytes, e.g. by adding additional chaotrope and/or
organic
solvents such as alcohols, in particular ethanol and/or iso-propanol;
- purification of the analytes, e.g. using silica based membranes, columns
or
silica magnetic bead based techniques;
- isolation of the analytes, e.g. using elution techniques;
- concentration of the analytes;
- collection of the analytes;
- stabilization of the purified / isolated analytes;
- storing of the purified / isolated analytes;
- analyzing, e.g. PCR-analysis.
It is in particular possible to use the processed tissue material resulting
from step (vi)
above as the starting material in known and commercially available
purification, isolation
and analysis tests or to use commercially available test kits for the further
processing.
The present invention further relates to the use of the compositions, the kits
and the
systems (combinations, kit-of-parts) as defined herein for treating (solid)
tissue material
as defined above. Therein treating preferably relates to disruption and/or
homogenization
as defined above, but may also comprise releasing or adding the tissue sample
to a
composition or mixture according to the present invention.
CA 02980120 2017-09-18
WO 2016/189132 23
PCT/EP2016/062002
The invention relates in particular to the following embodiments:
1. A composition for disrupting tissue material, comprising
- one or more solid disrupting particles;
- at least one enzyme for enzymatic lysis; and preferably
- at least one buffer;
and which does not comprise an alcohol in an amount, which denatures or
inactivates the enzymes.
2. The composition according to embodiment 1, further comprising one or
more
agents selected from
- at least one chaotropic agent, preferably guanidinium hydrochloride;
- at least one surfactant, preferably selected from the group of non-ionic
surfactants;
- at least one nuclease inhibitor;
- at least one anti-foaming agent;
- at least one osmotic stabilizer;
- at least one reducing agent;
and mixtures thereof.
3. The composition according to embodiment 1 or 2, further comprising at
least one
additional enzyme, other than the enzyme for enzymatic lysis, preferably an
RNase.
4. The composition according to any one of the preceding embodiments,
wherein the
at least one enzyme for enzymatic lysis is selected from the group of
proteases,
preferably proteinaseK.
5. The composition according to any one of the preceding embodiments,
wherein the
tissue material is selected from human and animal derived solid tissue.
6. The composition according to any one of the preceding embodiments,
comprising
at least one chaotropic agent in a total concentration equal to or less than
1M.
7. The composition according to any one of the preceding embodiments,
wherein the
solid disrupting particles exhibit a size of at least 1 mm.
CA 02980120 2017-09-18
WO 2016/189132 24 PCT/EP2016/062002
8. A kit for disrupting tissue material, the kit comprising
- one or more solid disrupting particles;
- at least one enzyme for enzymatic lysis;
- at least one buffer;
and optionally one or more agents selected from
- at least one chaotropic agent;
- at least one surfactant;
- at least one nuclease inhibitor;
- at least one anti-foaming agent;
- at least one osmotic stabilizer;
- at least one reducing agent;
- at least one additional enzyme, other than the enzyme for enzymatic
lysis,
preferably an RNase;
- at least one organic solvent, preferably an alcohol; and
- optionally a container for receiving the tissue material;
- and a leaflet with instructions for processing the tissue material.
9. A system comprising the composition as defined in any one of embodiments
1 to 7,
or the kit as defined in embodiment 8 and a device for effecting milling of
the tissue
material, preferably a high-power mixing mill, a high-speed mixer, or a low-
power
mixer, including a vortexer.
10. A system comprising the composition as defined in any one of
embodiments 1 to 7,
the kit as defined in embodiment 8, or the system as defined in embodiment 9,
further comprising a tissue material for disruption.
11. A method for disrupting tissue material, wherein the tissue material is
subjected to
a simultaneous treatment of
- mechanical disruption by grinding, milling or beating and
- chemical disruption by enzymatic lysis,
by grinding, milling or beating the tissue material in a lysis solution which
comprises one or more solid disrupting particles and at least one enzyme for
enzymatic lysis, and which does not comprise an alcohol in an amount, which
denatures or inactivates the enzymes.
CA 02980120 2017-09-18
WO 2016/189132 25 PCT/EP2016/062002
12. The method according to embodiment 11, wherein the lysis solution
further
comprises at least one chaotropic agent in a total concentration equal to or
less
than 1M.
13. The method according to embodiment 11 or 12, wherein disruption is carried
out by
using low-power mixers including vortexers, preferably by using vortexers.
14. The method according to any one of embodiments 11 to 13, which is
carried out by
using the composition as defined in any one of embodiments 1 to 7, the kit as
defined in embodiment 8 or the system as defined in embodiment 9 and 10.
15. The method according to any one of embodiments 11 to 14, comprising the
steps:
(i) adding to a tissue material in a suitable container
a) the one or more solid disrupting particles, the at least one buffer, the at
least one enzyme for enzymatic lysis, optionally an RNase, and optionally
one or more agents selected from chaotropic agents, surfactants, osmotic
stabilizers, reducing agents, nuclease inhibitors, anti-foaming agents or
mixtures thereof, or
b) the composition as defined in any one of embodiments 1 to 7;
(ii) optionally closing the container;
(iii) disrupting the tissue material in the container using a high-power
mixing mill, a
high-speed mixer, or a low-power mixer, including a vortexer, preferably by
using
a vortexer;
(iv) incubating the mixture of step (iv) at elevated temperature;
(v) optionally repeating step (iii) and (iv);
(vi) optionally providing the resulting mixture for subsequent purification,
separation, extraction and/or analytic process steps.
CA 02980120 2017-09-18
WO 2016/189132 26
PCT/EP2016/062002
Without limiting the scope of the present invention, the following examples
shall illustrate
the present invention:
Examples:
Extraction of DNA from rat tissue samples
Tissue Material:
rat, stabilized with RNALater (available from Qiagen)
Liver 25 mg, muscle 25 mg, lung 10 mg, kidney 20 mg, heart 10 mg
Equipment:
Container for receiving the tissue sample
Tube: 2m1 screw cap tube (PP, Sarstedt ¨ skirted base)
Disrupting particles
Bead: 5/32¨ Ballcone (ABBOTTBall),
round 5 mm stainless steel beads,
faceted zirconium beads
Device for effecting the milling / grinding
A) Vortex Genie 2 (Scientific Industries SI-V524), with various adapters:
foam insert,
horizontal and vertical Microtube Holder (VortexD)
B) TissueLyser II (available from Qiagen)
C) TissueLyser LT (available from Qiagen)
Lysis:
20 pl proteinaseK
4 pl RNaseA
200 pl AVE buffer and
pl VXL buffer (available from Qiagen)
Binding and Washing:
35 265 pl MVL buffer,
500 pl AW1 buffer,
500 pl AW2 buffer,
¨ 100 pl ATE buffer (available from Qiagen))
CA 02980120 2017-09-18
WO 2016/189132 27 PCT/EP2016/062002
Notes to the chemical agents
= ProteinaseK is very active in this concentration of chaotropic salt, but
likely any
concentration from 1M down to 0.5M Guanidine may be used.
= Tween20 and TritonX-100 are present as surfactants (detergents), though
other
surfactants would also be effective. Surfactants are not necessary for all
tissues,
but are not harmful to the process for any tissue, and improve the results
when
using particularly fatty tissue such as liver or brain.
= The chemistry is not restricted to column-based procedures, Silica
magnetic-
bead-based procedures are equally effective.
Protocol:
1. Excising the tissue sample or removing it from storage
2. Weighing and cutting the tissue sample into a suitably sized slice (5-25
mg), then
placing the piece into a 2 ml screw cap tube (Sarstedt 72.608+ blue cap
65.716.001),
adding one or more of the disrupting particles mentioned above, e.g. one 5/32¨
Bal!cone
(ABBOTTBall), or several of the round 5 mm beads or of the faceted zirconium
beads
3. Adding the lysis reagents and enzymes as listed above and closing the lid.
200p1 AVE / 40pIVXL / lpl DX Reagent / 20p1 Proteinase K / 4p1RNase A
(100mg/m1)
and closing the lid.
For processing multiple samples a master Digestion Buffer Mix can be prepared.
4. Proceeding with the homogenization:
A) Vortex Genie2 with appropriate 2 ml tube adapter: 5 minutes at full
speed (3200
rpm)
B) TissueLyser 11 with 2 x 24 2m1microcentrifuge adapter: 30 seconds at
24Hz
C) TissueLyser LT: 1-2 minutes at 30-45Hz
5. Incubating at 56 C and 1200 rpm in a Thermoshaker for 10 minutes
Note: Incubation proceeded after disruption regardless of visible residual
tissue.
If after incubation there was still residual tissue left, homogenization of
the tissue was
carried out a second time:
A) Vortex Genie2 with Vertical Microtube Holder: 3 minutes at full speed
(3200 rpm)
B) TissueLyser II: 15 seconds at 20Hz
CA 02980120 2017-09-18
WO 2016/189132 28
PCT/EP2016/062002
C) TissueLyser LT: 45 seconds at 30-40Hz
Then, the sample was incubated again at 56 C and 1200 rpm in a Thermoshaker
for 10
more minutes.
6. Opening the tube and adding 265 pl MVL buffer (available from Qiagen),
mixing by
pipetting or vortexing
7. Applying the mixture from step 6 to a QIAamp Mini Spin Column (available
from
Qiagen), closing the cap, followed by centrifugation for 1 minute at full
speed (not
exceeding 20000 x g), placing the Spin Column in a new 2 ml collection tube
and
discarding the collection tube containing the filtrate
8. Opening the Spin Column and adding 500 pl AW1 buffer (available from
Qiagen),
closing the cap, followed by centrifugation for 30 seconds at full speed (not
exceeding
20000 x g), placing the Spin Column in a new 2 ml collection tube and
discarding the
collection tube containing the filtrate
9. Opening the Spin Column and adding 500 pl AW2 buffer (available from
Qiagen),
closing the cap, followed by centrifugation for 30 seconds at full speed (not
exceeding
20000 x g), placing the Spin Column in a new 2 ml collection tube and
discarding the
collection tube containing the filtrate
10. Centrifugation at full speed for 2 minutes (to eliminate the chance of
possible AW2
carryover), placing the Spin Column in a clean 1.5 ml microcentrifuge tube
11. Opening the Spin Column and adding 100 pl ATE buffer (available from
Qiagen),
incubation at room temperature for 1 minute, followed by centrifugation at
full speed (not
exceeding 20000 x g) for lminute
12. Repeating step 11.
A. Determination of yield across multiple sample types compared to classic
ProteinaseK digestion
Determination of the yield
UV-VIS-spectrophotometer (Nanodrop) / DNA-specific fluorescent assay (Qubit
2.0);
0,6 %TAE gel:
18 h 20 volt,
template: same volume of eluate
QFPathogenmitICDNA-Assay with 12000 copies ICDNA/reaction and 1 p1/6p1eluate
addition.
Test Results:
0
t..)
Table 1
=
,-,
Disruption / Disruption
,-,
Mechanical Chemical Disruption /
cio
Prep Lysis Buffer +Buffer
Device / Binding DNA Yield [mg], MV n=2 yD
Disruption Incubation
,-,
Mix Particle
t..)
I
II III
1/11 III 1/11 III
Lung limg Liver 25mg Muscle 25mg
2000 PBS
400 VXL / 53,55
39,504 10,9872
w/o Azid
20 I PK / 265p.I
2000 PBS
40 RNaseA
MVL 36,306 37,824 5,8458
w/Azid Vortex (D) + 56 C/
/ 1p1 DX 5min full 8min full
2000 H20 5/32" 1000rpm /
30,324 46,176 8,9544
speed speed
P
ballcone 20min
2000 AL .
rõ
180pIATL / /
2000 .3
-
23,904 30,558 5,1756 ,
200 PK 96-
100%
yD
.
56 C/
rõ
QIAamp
Et0H .
,
1000rpm /
,
,
Fast 200 I PBS
.
400 VXL / 15min 49,44
39,17 8,43 '
,
w/o Azid
,
.3
20111 PK / 265111
200 I PBS
40 RNaseA
MVL 38,23 44,61 8,21
w/Azid TissueLyser II 56 C/
/ 1p1 DX 1min
200 I H20 +5/32- 1min 24Hz 1000rpm /
52,89 47,62 8,31
24Hz
ballcone 15min
200p.I AL
1800 ATL / /
200p.I
-
30,04 46,45 7,93
200 PK 96-
100%
1-d
Et0H
n
1-i
56 C /
200p.I AL
m
1-d
QIAamp 1800 ATL - - -
/ 200111 t..)
100Orpm /
6,33 30,88 1,27 =
Mini +20 I PK 96-
100% ,-,
120min
Et0H
'a
t..)
o
Material: Rat tissue, RNALater stabilized; Vortex (D): VortexGenie2 +Vertical
Microtube Holder(SI-V524) o
t..)
Table 2
0
Disruption / Disruption
t..)
Chemical Disruption
o
,-,
Prep Lysis Buffer +Buffer Device /
mechanical Disruption Binding DNA Yield [ig], MV n=2
/ Incubation ,-,
Mix Particle
oe
yD
I
II III
1/111 II 1/111 II
t..)
Lung 14mg Muscle 25mg Kidney 20mg
2000 PBS
400 VXL /
36 8,586 50,28
w/o Azid Vortex (D) + 56 C / 56 C /
20 I PK /5min full 8min full
2000 PBS 5/32" 1000rpm 1000rpm
265111MVL
4 1 RNaseA speed speed
45,18 9,132 53,58
w/Azid ballcone / 15min
/ 20min
QIAamp 2000 H20
31,8 9,672 45,54
Fast 200 I PBS
400 VXL /
30,54 6,37 58,98 P
w/o Azid TissueLyser 56 C / 56 C /
20 I PK /
265111
200 I PBS II +5/32" 1min 24Hz 1min 24Hz 1000rpm 1000rpm
-
40 RNaseA MVL
31,74 7,19 67,20 '
.
w/Azid ballcone / 15min
/ 15min ,
/ 11.11 DX
=
200 I H20
29,88 6,74 67,20
.
,
200111AL /
.
QIAamp 180 I ATL56 C / 1000rpm / 200111
- - -
1,51 0,10 0,99
Mini +20 1PK 150min
96-100%
Et0H
Material: Rat tissue, RNALater stabilized; Vortex (D): VortexGenie2 +Vertical
Microtube Holder(SI-V524)
1-d
n
m
t..)
=
'a
t..)
=
=
t..)
0
t..)
Table 3
=
,-,
Dsiruption / Disruption
Mechanical Chemical Disruption
cio
Prep Lysis Buffer +Buffer
Device / Binding DNA Yield [m], MV n=2 vD
Disruption / Incubation
,-,
Mix Particle
c,.)
t..)
I Muscle
II III
I 11/111 I 11/111
25mg
Liver 25mg Lung 11mg
200 I PBS
12,78
45,18 48,42
40 1VXL / w/o Azid
20 1PK / 200111 PBS
Vortex (D) + 56 C /
8min full 5min full
4 1RNaseA w/Azid speed speed
5/32" 1000rpm
10,95 44,04 23,34
ballcone / 20min
/ 11.11 DX 200111 H20
10,368 46,32 32,4
56 C/
P
QIAamp 2000 AVE
8,19 48,06 35,04 o
"
1000rpm / 2650 MVL -
Fast 200 I PBS
00
10min
9,37 72,60 49,32 ,
40 1VXL / w/o Azid
TissueLyser 56 C/
"
.
20 1PK / 200 1 PBS 1min
,
4 1RNaseA w/Azid 11+5/32-
24Hz 1min 24Hz 1000rpm 7,27 55,62 56,76 ,
,
.
ballcone / 10min
/ 1 1 DX 200 1H20
7,28 70,80 52,86 3
200m1 AVE
5,34 71,34 66,60
200111 AL/
QIAamp 180 I ATL +56 C / 1000rpm /
200 I 96-
- - -
0,00 0,47
Mini 201.11PK 150min 100%
Et0H
Material: Rat tissue, RNALater stabilized; Vortex (D): VortexGenie2 +Vertical
Microtube Holder(SI-V524) 1-d
n
m
t..)
=
'a
t..)
=
=
t..)
Table 4
0
Dsiruption / Chemical
Disruption t..)
Disruption
o
,-,
Prep Lysis Buffer +Buffer
Mechanical Disruption / Incubation Binding DNA Yield [pg], MV n=2
Device / Particle
,-,
Mix
cio
yD
II
t..)
I II I II
Muscle
Heart 10mg
25mg
2000 PBS
12,462 15,96
400 VXL / w/o Azid
20 I PK / 2000 PBS Vortex (D) + 8min full 5min full 56
C /
40 RNaseA w/Azid 5/32" ballcone speed speed 1000rpm
8,988 13,02
/ 20min
/ 1p1 DX 2000 H20
8,568 13,956
P
QIAamp 200p 56
c/IAVE 11,982 14,76
1000rpm 265p.I MVL
o
rõ
Fast 2000 PBS
-
.
/ 10min
14,52 15,06 o
,
400 VXL / w/o Azid
56 C/
t..) .
rõ
20 I PK / 2000 PBS TissueLyser II
.
1min 24Hz 1min 24Hz 1000rpm
13,68 19,56 ,
,
'
40 RNaseA w/Azid +5/32"ballcone
.
/ 10min
-
,
/ 1p1 DX 200p.I H20
11,13 17,94 ,
.
200m1 AVE
10,49 16,02
200p.I AL/
QIAamp 180p.I ATL +2001_1196-
- - - 56 C
/ 1000rpm / 180min 0,08 0,99
Mini 200 PK
100%
Et0H
Material: Rat tissue, RNALater stabilized; Vortex (D): VortexGenie2 +Vertical
Microtube Holder(SI-V524)
Iv
n
m
t..)
=
'a
t..)
=
=
t..)
CA 02980120 2017-09-18
WO 2016/189132 33
PCT/EP2016/062002
Yields of nucleic acid from tissue types were up to 20-fold improved over a
standard
proteinaseK digestion. Overall digestion time was also reduced by a factor of
five
compared to proteinaseK digestion alone (in both cases, digestion was carried
out until
the sample appeared visibly homogenous).
Average proteinaseK digestion time (without mechanical milling) was 150
minutes, while
the new method achieved homogenization in generally less than 30 minutes.
The experiment also shows that equivalent yields can be achieved on a common
laboratory vortexter (low-power device) and in an expensive high-power bead
mill.
Further, it has been shown that also DNA quality (DNA size) was improved
through the
use of vortexer.
B. Experimental time effort compared to classic ProteinaseK digestion
The effectiveness of the method of the present invention has been evaluated in
view of
the time effort compared to classic proteinaseK digestion, applying the test
conditions as
given above.
Test Results
Table 5
0
Disruption/
t..)
Disruption Chemical
Disruption /
,--,
Prep Lysis Buffer Mechanical Disruption
Binding DNA Yield [pg], MV n=2
Device / Particle Incubation
,--,
Mix
cio
yD
1.Disruption 2.Disruption 56 C / 1000rpm I II III IV
,--,
t..)
Mouse Mouse tail
Liver Kidney
1-1V only 1 /11 1 11 III/IV
tail 10mg 40-55mg
25mg 18mg
Vortex (D) +
2651.11
5min 3min 10,668 6,864 28,08 45,96
5/32" ballcone 10min
MVL
20min 20min
TissueLyser II 30sec.24Hz 15sec.20Hz
8,886 8,904 32,22 61,2
+5/32"ballcone 1min 20Hz 15sec.20Hz
- 9,048 7,5 - -
Vortex (D) +
5min 3min 7,77 7,368 26,64 40,5
p
5/32" ballcone 60min
.
2000 AVE /70min 70min
"
TissueLyser II 30sec.24Hz 15sec.20Hz
8,064 8,94 30,42 60,18 .3
.
400 VXL /
,
QIAamp +5/32"ballcone 1min 20Hz 15sec.20Hz
- 7,806 7,242 - - .6. .
20 I PK /
"
.
Fast Vortex (D) +
,
40 RNaseA 5min -
- - 22,26 40,26 ,
,
5/32" ballcone 180min
/ 1p1 DX
,
,
TissueLyser II 30sec.24Hz - _
_ - - 26,7 65,4 03
+5/32"ballcone 1min 20Hz -
- - - - -
Vortex (D) +
5min 3min 1,656 - 29,76 49,98
5/32" ballcone o/n
o/n -
TissueLyser II 30sec.24Hz 15sec.20Hz
0,84 - 18 71,4
+5/32"ballcone 1min 20Hz 15sec.20Hz
- 0,4548 - - -
60min
2001.iIAL - - 0,23 3,10 1-d
n
QIAamp 180p.I ATL +_ _ _ 120min /
200p1 - - 0,333 -
m
1-d
Mini 200 PK 180min 96-
100% - 0,4416 5,42 t..)
o
o/n Et0H
3,70 9,41 0,3852 1,76 ,--,
'a
Material: Rat liver, RNALater stabilized // Mouse tail, fresh-frozen; Vortex
(D): VortexGenie2 +Vertical Microtube Holder(SI-V524)
t..)
o
o
t..)
Table 6
0
Disruption
Inhibition PCR: QuantiFast t..)
Disruption Chemical
Disruption / =
Prep / Lysis Mechanical Disruption
Binding Pathogen+ICDNA (12000copies/reaction) ,--,
Device / Particle Incubation
Buffer Mix
[ct value], MV ,--,
cio
yD
Mouse tail 10mg
Mouse tail 40-55mg 1-
1.Disruption 2.Disruption 56 C /
1000rpm w
(1)
(II)
1 p.I
10111 1 p.I 10111
I-1V only 1 /II I II III/1V
eluate
eluate eluate eluate
Vortex (D) +
265p.I 29,29 45 29,11 45
5min 3min
5/32" ballcone 10min
MVL
20min 20min
TissueLyser II 30sec.24Hz 15sec.20Hz
28,195 45 27,755 42,79
+5/32"ballcone 1min 20Hz 15sec.20Hz - 28,6 45 27,655
41,825
Vortex (D) +
27,62 42,89 27,61 30,49 P
5min 3min
.
rõ
2000 AVE 5/32" ballcone 60min
'
70min 70min
/ 400 VXL TissueLyser II 30sec.24Hz 15sec.20Hz
28,05 36,64 27,58 32,035 ,
u,
.
QIAamp / 200 PK / +5/32"ballcone 1min 20Hz 15sec.20Hz - 27,355
35,135 27,52 31,38 rõ
.
,
,
'
Fast 4 1 Vortex (D) +
.
5min - - - - -
'
,
RNaseA / 5/32" ballcone 180min
,
.
1p.I DX TissueLyser II 30sec.24Hz -
- - - - - -
+5/32"ballcone 1min 20Hz - -
- - - -
Vortex (D) +
27,36 28,98
5min 3min - -
5/32" ballcone o/n
o/n -
TissueLyser II 30sec.24Hz 15sec.20Hz
27,31 30,085 - -
+5/32"ballcone 1min 20Hz 15sec.20Hz - 27,24 28,47 - -
Iv
n
60min
2001.LIAL - - - -
m
QIAamp 180 I ATL 120min
/2001.11 - - - - Iv
t..)
Mini + 200 _ _ _ PK 180min 96-
100% - - - - o
,--,
'a
o/n Et0H
40,2 45 43,62 45
t..)
o
o
t..)
CA 02980120 2017-09-18
WO 2016/189132 36 PCT/EP2016/062002
Additional information table6: IC DNA: ct value = 27,37; ct value =27,85 (MV,
n=4)
The new method can achieve higher yields in 10 min disruption + 10 min
proteinaseK
digestion than are achieved overnight (o/n) (more than 8 hours) with enzymatic
digestion
alone.
The experiment also shows effectiveness of the new method with very difficult
tissue
material, such as mouse tail.
C. Evaluation of the performance with different disrupting particles
The effectiveness of the method of the present invention has been evaluated in
view of
different disrupting particles, applying the test conditions as given above.
Test results
Table 7
0
Disruption / Disruption Chemical DNA
Yield t..)
Mechanical
o
,¨,
Prep Lysis Buffer Device /
Disruption Particle Disruption / Binding [ps], MV o,
Disruption
,¨,
Mix Particle
Incubation n=2 cio
yD
56 C/
1,4mm Ceramic Beads 10min
20min 265111 MVL 17,46 t..)
100Orpm
2mm Ceramic Pearls 5min
10min 265 I MVL 20,22
GlassBeads PathogenLysisTubeL
10min
70min 265111 MVL 23,4
200 1 AVE / (<1mm) QIAGEN
Vortex (D) +
40 I VXL / 0,8-1mm Diamond Pearls 10min 70min 265111
MVL 17,544
QIAamp 5/16"
20p.I PK /
Fast ballcone Mesh30/40 Garnet Sand 10min
20min 265111 MVL 11,79
4 I RNaseA
(full speed) 0,7mm Garnet Flakes 5min 10min 265
I MVL 15,78
/ 1 I DX
P
1/8" Ballcone 10min
20min 265111 MVL 29,04 .
rõ
3x 1/8" Ballcone 5min
10min 265 I MVL 27,84 .
,
3/16" Ballcone 5min
10min 265111 MVL 29,34
rõ
.
5/32" Ballcone 5min
10min 265 I MVL 27,72 ,
,
,
.
'
200 I AL /
,
QIAamp 1800 ATEL 56 C/
00
- - - -
150min 200 I 96- 0,5754
Mini + 20 I PK 1000rpm
100% Et0H
Material: Liver, Rat, RNALater stabilized, 15mg; Vortex (D): VortexGenie2
+Vertical Microtube Holder(SI-V524)
1-d
n
m
t..)
o
,¨,
o
O-
o
t..)
o
o
t..)
CA 02980120 2017-09-18
WO 2016/189132 38
PCT/EP2016/062002
The new chemistry is not restricted to a specific form of disrupting particle.
It has been shown that with the composition of the present invention DNA
quality was
equally high when using round 5 mm beads or the 5/32¨ Bal!cone.
When using round 5 mm beads, the disruption tended to be decreased and more or
larger tissue residues remained compared to the 5/32¨ Bal!cone disruption.
Lysis times were essentially the same, however the disruption with the
vortexer achieved
slightly lower yields, depending on the used tissue material.
D. Evaluation of different tissue types
The effectiveness of the method of the present invention has been evaluated in
view of
different tissue materialsõ applying the test conditions as given above.
Test results
0
t..)
o
Table 8
o,
Chemical
Disruption / Disruption
cio
vD
Mechanical Disruption
Prep Lysis Buffer Device / Binding
DNA Yield [m], MV n=2 c,.)
Disruption
/ t..)
Mix Particle
Incubation
56 C / Liver, Brain, Lung,
Heart, Kidney, Spleen, Esophagus, Trachea, Ear, Fat,
Rat Rat Rat Rat Rat Rat Rat Rat Rat Rat
100Orpm
10mg 10mg 10mg 10mg 10mg 10mg
10mg 10mg 10mg 20mg
400 VXL /
Vortex (D)
200 PK / 5min 265 I
+ 5/32" 10min 13,92 4,28 11,848 5,608 15,664 63,52 13,432
23,6 21,36 1,5328
4 IRNaseA full speed MVL
ballcone
P
/ 1 IDX
.
rõ
400 VXL /
TissueLyser
,
QIAamp 200 PK / 265 I
vD .
II + 5/32" 30sec.24Hz 10min 15,528 6,808 8,944
6,968 19,76 87,52 10,352 55,92 24,24 1,6264 rõ
Fast 4 IRNaseA MVL
,
ballcone
,
,
/ 1 IDX
.
,
400 VXL /
,
.
TissueLyser
200 PK / 265 I
LT + 5/32" 2min 45Hz 10min 14,104 7,392 19,76
6,544 18,88 52,8 12,144 73,68 23,92 1,5968
41.1IRNaseA MVL
ballcone
/ 1 I DX
200 I
AL /
QIAamp 1800 ATL +200 I
- - o/n 2,39 0,35 1,54 0,88
5,30 7,22 1,23 1,33 4,06 0,78 1-d
Mini 200 PK 96-
n
,-i
100%
m
Et0H
1-d
t..)
o
Material: fresh-frozen; Vortex (D); VortexGenie2 +Vertical Microtube Holder(SI-
V524)
'a
t..)
o
o
t..)
0
Table 9
t..)
o
Chemical
,¨,
Disruption / Disruption Device / Mechanical Disruption
Prep Binding DNA
Yield Big], MV n=2 yD
Lysis Buffer Mix Particle Disruption /
t..)
Incubation
II=Tail,
III=Ear,
I=Tail(tip),
56 C /
Mouse Pig MV,
Rat 0,5cm
1000rpm
n=1 1cmx0,2cm 10mg
n=1
n=2
Vortex (D) + 5/32" 2x 5min
1=70min 265 I MVL
28 7,696 10,28
ballcone full speed
400 VXL / 20111
QIAamp TissueLyser II + 5/32" 2x
Q
PK/ 4 IRNaseA 11=50min 265 I MVL
38,08 14,752 10,392 c,
Fast ballcone 30sec.24Hz
rõ
/ 1 I DX
TissueLyser LT + 5/32" 2x 2min
0
,
II1=20min 265 I MVL
28,16 14,448 10,856
o .
ballcone 45Hz
rõ
0
56 C/ 2001.tI AL /
,
,
QIAamp 180 IATL +
,1,
- - 1000rpm / 2000 96-100%
8,40 10,22 0,84 .
,
Mini 20111 PK
,
o/n Et0H
.3
Material: fresh-frozen; Vortex (D): VortexGenie2 +Vertical Microtube Holder(SI-
V524)
1-d
n
m
t..)
=
'a
t..)
=
=
t..)
CA 02980120 2017-09-18
WO 2016/189132 41
PCT/EP2016/062002
The improvements as described herein can be achieved with different kinds of
tissue
samples, such as soft tissue materials and even with tough tissue materials
such as
mouse tail.
E. Evaluation of synergistic effects
The effectiveness of the combination of mechanical and chemical (enzymatic)
lysis
compared to the individual treatments has been evaluated, applying the test
conditions
as given above.
Test results:
Table 10
0
visual assessment of Binding t..)
o
Disruption
Yield
Disruption Chemical disruption homogenization
Buffer
Prep Device/
,-,
cio
Buffer incubation Liver Muscle
yD
Particle Liver Muscle
,-,
mg
10 mg c,.)
t..)
2000 AVE /
Combined
Vortex (D) + 40 I VXL / 20 I
chemical and 56 C / 1000rpm /
5/16" PK / 4 I ok ok
265 I MVL 25,14 3,49
mechanical 10min
ballcone RNaseA / 1 I
disruption
DX
2200 AVE /
Mechanical Vortex (D) +
40 I VXL / 4 I - tiny pieces
of
disruption 5/16" ok
265 I MVL 5,45 0,75 Q
RNaseA / 1 I tissue
left .
only ballcone
rõ
DX
'
.3
,
2000 AVE /
t..)
.
Chemical
rõ
40 I VXL / 20 I 56 C / 1000rpm / tiny
pieces of .
disruption - ok
265111 MVL 1,05 0,9 ,
,
'
PK / 4 I 150min tissue left
.
only
-
,
RNaseA
,
.3
MV, n=2
1-d
n
1-i
m
Iv
w
o
1¨
'I-
w
o
o
w
CA 02980120 2017-09-18
WO 2016/189132 43
PCT/EP2016/062002
Yields are in micrograms, as measured by a DN- specific flourescent assay
(Qubit 2.0)
A synergistic effect (x-fold improvement over sum of both individual methods)
can be
seen:
Liver 10 mg Muscle 10 mg
3,87 2,12
F. Evaluation of improvement versus commercially available test kits
The effectiveness of the composition of the present invention compared to
several
commercially available test kits has been evaluated.
Test results:
0
w
o
1¨
Table 1 1
o
1¨
cio
DNA Yield [Rd, MV n=2 vD
,-,
Disruption tube / Disruption
Chemical Disruption / RNALater 10mg c,.)
t..)
Company Prep Kit
Disruption Particles Device Incubation
I II 111
Kidney, Rat
Liver, Rat Lung, Rat
ZR Genomic DNA-
- - PK-Iysis 55 C/
o/n 3,365 10,685 5,85
Tissue Mini Prep
Zymo
Quick-gDNA Mini
-
Squisher - -
1,92 1,655 1,575
Prep
FastDNA Green LysingMatrixD (2m1
Fast Prep - -
4,46 1,9 3,775 p
Spin Kit - Prep1 Screwcap tube with
.
"
MPBio FastDNA Green 1.4mm ceramic
.
.
Spin Kit - Prep2 sphere) +6mm Fast Prep - -
2,0345 0,9555 0,8155 ,
4=,
0
(Rep.) ceramic sphere
"
.
,
,
,
PureLink Genomic 55 C / vortex
-
'
lnvitrogen - - PK-lysis now and again / 1,715 0,644
2,89 ,
DNA Mini Kit
240min
TD1 solution (GuHCI, vortex - -
16,2 6,615 9,565
lsopropanol)
UltraClean
Dry Bead tube (2m1
MoBio Tisue&Cells DNA
Screwcap tube with vortex PK-Iysis 60 C / 30min
11,45 3,615 14,9
Isolation
0.7 mm Garnet
Flakes)
1-d
n
m
w
o
1¨
'I-
w
o
o
w
0
t..)
o
,-,
o
,-,
Table 12 (continued)
cio
o
,-,
t..)
DNA Yield [iig], MV n=2
Disruption tube / Disruption
Chemical Disruption / RNALater 10mg
Company Prep Kit
Disruption Particles Device Incubation
I II 111
Kidney, Rat
Liver, Rat Lung, Rat
56 C / 100Orpm /
- - PK-Iysis
2,705 0,4025 2,285
180min
56 C / 1000rpm /
QIAGEN QIAamp Mini - - PK-lysis
1,315 0,4485 1,98
o/n
P
no disrupting TissueRuptor
Iysis 56 C / 1000rpm / .
rõ
PK-
5,885 7,585 10,05
particles (mixer) 120min
,
56 C / 1000rpm / u, .
rõ
.
vortex (D) PK-lysis 10min (1,11)
/ 35,9 23 52,95 ,
,
,
.
Tissue Disruption 20min
(111) -
,
,
Tube (2m1Screwcap 56 C / 1000rpm / .3
TissueLyser
QIAGEN QIAamp Fast tube with skirted PK-lysis 10min (1,11)
/ 27,95 24,5 59
11
base and 5/32" 20min
(111)
ballcone) 56 C / 1000rpm /
TissueLyser
PK-lysis 10min (1,11) /
42,6 29,2 33,6
LT
20min (111)
1-d
n
1-i
m
Iv
t..)
o
,-,
o
O-
o
t..)
o
o
t..)
Table 13
0
Prep Time jmin]
t..)
o
,¨,
RNALater 10mg
Disruption tube / Disruption
Company Prep Kit Chemical
Disruption / Incubation II cio
Disruption Particles Device
IIII yD
,¨,
Liver,
c,.)
Kidney, Rat
Rat Lung, Rat t..)
ZR Genomic DNA-
- - PK-Iysis 55 C/ o/n 1200 1200 1200
Zymo Tissue Mini Prep
Quick-gDNA Mini Prep- Squisher - - 25 25
25
FastDNA Green Spin LysingMatrixD (2m1
Fast Prep - -
100 100 100
Kit - Prep1 Screwcap tube with
MPBio
FastDNA Green Spin 1.4mm ceramic sphere)
Fast Prep --
110 110 110
Kit - Prep2 (Rep.) +6mm ceramic sphere
P
.
PureLink Genomic DNA
55 C / vortex now and
Invitrogen -
.
- PK-lysis
265 265 265
c,
Mini Kit
again / 240min,
.6.
.
TD1 solution (GuHCI, vortex - -
30 30 30 rõ
c,
,
Isopropanol)
,
,
UltraClean Tisue&Cells
.
,
MoBio Dry Bead tube (2m1
DNA Isolation vortex PK-Iysis 60 C
/ 30min 60 60 60 ,
.3
Screwcap tube with 0.7
mm Garnet Flakes)
- 56 C / 1000rpm /
- PK-Iysis
200 200 200
180min
QIAGEN QIAamp Mini- - PK-Iysis
56 C / 1000rpm / o/n 1200 1200 1200
TissueRuptor Iysis
56 C / 1000rpm /
no disrupting particles PK-
150 150 150
(mixer)
120min 1-d
n
56 C / 1000rpm / 10min
vortex (D) PK-Iysis
35 35 45 m
Tissue Disruption Tube
(1,11)/ 20min (111) 1-d
t..)
(2m1 Screwcap tube with
56 C / 1000rpm / 10min o
,¨,
QIAGEN QIAamp Fast TissueLyserll PK-Iysis
30 30 40
skirted base and 5/32"
(1,11)/ 20min (111) 'a
ballcone)
56 C / 1000rpm / 10min t..)
o
TissueLyser LT PK-Iysis
35 35 45 o
(1,11)/ 20min (111) t..)
Table 14
0
DNA Yield [11g],
Prep Time t..)
o
,¨,
Disruption tube / Disruption
n=1 [min]
Company Prep Kit
Chemical disruption / Incubation
Disruption Particles Device
IV cio
yD
Mousetail, fresh-frozen, lcm
t..)
ZR Genomic DNA-
- - PK-lysis 55
C/ an 17 1200
Zymo Tissue Mini Prep
Quick-gDNA Mini Prep - Squisher -
- 4,58 25
FastDNA Green Spin LysingMatrixD (2m1
Fast Prep -
- 0,367 100
Kit - Prep1 Screwcap tube with 1.4mm
MPBio
FastDNA Green Spin ceramic sphere) +6mm
Fast Prep -
- 0,262 120
Kit - Prep2 (Rep.) ceramic sphere
PureLink Genomic DNA
55 C/ vortex now and P
Invitrogen - - PK-Iysis
5,1 265 o
"
Mini Kit
again/ o/n .
.3
.
TD1 solution (GuHCI, vortex -
- 0 30,
4=.
Iv
-4
0
Isopropanol)
"
.
UltraClean Tisue&Cells
,
MoBio Dry Bead tube (2mI
,
,
DNA Isolation vortex PK-Iysis 60
C / 30min 0,109 60
,
Screwcap tube with 0.7 mm
,
.
Garnet Flakes)
56 C / 1000rpm /
vortex (D) PK-Iysis
10,4 45
20min (IV)
Tissue Disruption Tube (2m1
56 C / 1000rpm /
QIAGEN QIAamp Fast Screwcap tube with skirted TissueLyser II
PK-Iysis 20,5 40
10min (IV)
base and 5/32" ballcone)
56 C / 1000rpm /
TissueLyser LT PK-Iysis
11,8 45
10min (IV)
1-d
n
Vortex (D): VortexGenie2 +Vertical Microtube Holder(SI-V524)
m
1-d
t..)
o
The composition of the present invention achieves improved yields with minimum
to no DNA degradation (improved DNA quality) with improved
'o--,
o
time effort compared to commercially available kits.
t..)
o
o
t..)
